163 related articles for article (PubMed ID: 20371759)
1. Adherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylurea.
Thayer S; Arondekar B; Harley C; Darkow TE
Ann Pharmacother; 2010 May; 44(5):791-9. PubMed ID: 20371759
[TBL] [Abstract][Full Text] [Related]
2. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
3. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
Barner JC
Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
[TBL] [Abstract][Full Text] [Related]
4. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.
Cheong C; Barner JC; Lawson KA; Johnsrud MT
Clin Ther; 2008 Oct; 30(10):1893-907. PubMed ID: 19014846
[TBL] [Abstract][Full Text] [Related]
5. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
[TBL] [Abstract][Full Text] [Related]
6. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
7. Oral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimens.
Vittorino Gaddi A; Benedetto D; Capello F; Di Pietro C; Cinconze E; Rossi E; De Sando V; Cevenini M; D'Alò G
Public Health; 2014 Jan; 128(1):70-6. PubMed ID: 23969148
[TBL] [Abstract][Full Text] [Related]
8. [Clinical utilization of combined rosiglitazone and glimepiride in the treatment of type 2 diabetes mellitus].
Fehér J; Lengyel G
Orv Hetil; 2007 Dec; 148(49):2331-5. PubMed ID: 18048112
[TBL] [Abstract][Full Text] [Related]
9. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study.
Herman WH; Dirani RG; Horblyuk R; O'Neill MC; Kravitz B; Heise MA; Bakst A; Freed MI;
Am J Manag Care; 2005 Apr; 11(4):273-8. PubMed ID: 15839187
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
11. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
13. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
Chou HS; Palmer JP; Jones AR; Waterhouse B; Ferreira-Cornwell C; Krebs J; Goldstein BJ
Diabetes Obes Metab; 2008 Aug; 10(8):626-37. PubMed ID: 17645558
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
Lee WC; Conner C; Hammer M
Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
[TBL] [Abstract][Full Text] [Related]
16. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
17. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination.
Pfützner A; Wilhelm B; Forst T
Vasc Health Risk Manag; 2007; 3(2):211-20. PubMed ID: 17580731
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes.
Hutchins V; Zhang B; Fleurence RL; Krishnarajah G; Graham J
Curr Med Res Opin; 2011 Jun; 27(6):1157-68. PubMed ID: 21466277
[TBL] [Abstract][Full Text] [Related]
20. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
Riedel AA; Heien H; Wogen J; Plauschinat CA
Pharmacotherapy; 2007 Aug; 27(8):1102-10. PubMed ID: 17655510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]